Source:http://linkedlifedata.com/resource/pubmed/id/20023904
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
48
|
pubmed:dateCreated |
2009-12-21
|
pubmed:abstractText |
The conjugation of porphyrins to metal fragments is a strategy for making new compounds that are expected to combine the phototoxicity and the tumour-localization properties of the porphyrin chromophore with the cytotoxicity of the metal fragment for additive antitumour effect. We report here the preparation of new classes of porphyrin-ruthenium conjugates with potential bio-medical applications. Ruthenium was chosen because several Ru compounds have shown promising anticancer activity. The conjugation with the porphyrin moiety was accomplished either through peripheral pyridyl rings (e.g.meso-4'-tetrapyridylporphyrin, 4'TPyP) or through bpy units (e.g.meso-(p-bpy-phenyl)porphyrins, bpy(n)-PPs, n = 1-4). The number of Ru fragments attached to the porphyrins ranges from 1 to 4 and the total charge of the conjugates from -4 to +8. Different types of peripheral fragments, both Ru(III) and Ru(II), have been used: in some cases they are structurally similar to established anticancer compounds. Examples are [Na](4)[4'TPyP{trans-RuCl(4)(dmso-S)}(4)] (2), that bears four NAMI-type Ru(III) fragments, or [4'TPyP{Ru([9]aneS3)(en)}(4)][CF(3)SO(3)](8) (3) and [bpy(4)-PP{Ru([9]aneS3)(dmso-S)}(4)][CF(3)SO(3)](8) (9) (en = ethane-1,2-diamine, [9]aneS3 = 1,4,7-trithiacyclononane) that have four half-sandwich Ru(II) compounds. The Ru fragments may either contain one or more labile ligands, such as in 2 or in 9, or be coordinatively saturated and substitutionally inert, such as in 3 or in [bpy(4)-PP{Ru([12]aneS4)}(4)][CF(3)SO(3)](8) (11) ([12]aneS4 = 1,4,7,10-tetrathiacyclododecane). Most of the ruthenium-porphyrin conjugates described in this work are soluble--at least moderately--in aqueous solution and are thus suitable for biological investigations, in particular for cytotoxicity and photo-cytotoxicity tests.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1477-9234
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10742-56
|
pubmed:meshHeading |
pubmed-meshheading:20023904-Antineoplastic Agents,
pubmed-meshheading:20023904-Coordination Complexes,
pubmed-meshheading:20023904-Crystallography, X-Ray,
pubmed-meshheading:20023904-Magnetic Resonance Spectroscopy,
pubmed-meshheading:20023904-Molecular Conformation,
pubmed-meshheading:20023904-Porphyrins,
pubmed-meshheading:20023904-Ruthenium
|
pubmed:year |
2009
|
pubmed:articleTitle |
Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity.
|
pubmed:affiliation |
Department of Pharmaceutical Sciences, University of Trieste, 34127, Trieste, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|